RC
ABCL icon

Renaissance Capital’s AbCellera Biologics ABCL Stock Holding History

Renaissance Capital’s Portfolio ABCL Stock Details ABCL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q2 		– Sell
-7,957
Closed -$60K – 76
2023
Q1 		$60K Sell
7,957
-1,019
-11% -$9.25K 0.04% 87
2022
Q4 		$90.9K Buy
+8,976
New +$104K 0.07% 86
2022
Q1 		– Sell
-10,327
Closed -$148K – 101
2021
Q4 		$148K Sell
10,327
-1,815
-15% -$27.5K 0.04% 107
2021
Q3 		$243K Sell
12,142
-16,349
-57% -$289K 0.05% 100
2021
Q2 		$627K Sell
28,491
-6,270
-18% -$173K 0.1% 71
2021
Q1 		$1.18M Buy
+34,761
New +$1.38M 0.17% 57

Other funds holding ABCL

Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
VOYA Investment Management
VOYA Investment Management Atlanta, Georgia $96.1B AUM 40.06% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
CS
Credit Suisse Zurich, Switzerland $104B AUM 34.76% 1-Year Est. Return
O
OrbiMed New York $4.59B AUM 125.28% 1-Year Est. Return
ACH
ArrowMark Colorado Holdings Denver, Colorado $3.76B AUM 21.77% 1-Year Est. Return
FFVM
Founders Fund VII Management San Francisco, California $2.03M AUM 72.34% 1-Year Est. Return
BlackRock
BlackRock New York $5.7T AUM 30.48% 1-Year Est. Return
Federated Hermes
Federated Hermes Pittsburgh, Pennsylvania $61.5B AUM 30.7% 1-Year Est. Return